Net profit of Jagsonpal Pharmaceuticals declined 49.17% to Rs 3.96 crore in the quarter ended December 2023 as against Rs 7.79 crore during the previous quarter ended December 2022. Sales declined 21.43% to Rs 47.25 crore in the quarter ended December 2023 as against Rs 60.14 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales47.2560.14 -21 OPM %7.1714.37 - PBDT5.6810.20 -44 PBT5.279.87 -47 NP3.967.79 -49 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 February 2024.Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals has allotted 89,794 equity shares under ESOP on 04 December 2023. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs.13,09,90,000 (constituting of 2,61,98,000 equity shares of Rs. 5/- each) to Rs.13,14,38,970 (constituting of 2,62,87,794 equity shares of face value of Rs. 5/- each).Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals declined 28.24% to Rs 7.47 crore in the quarter ended September 2023 as against Rs 10.41 crore during the previous quarter ended September 2022. Sales declined 4.46% to Rs 57.83 crore in the quarter ended September 2023 as against Rs 60.53 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales57.8360.53 -4 OPM %14.4721.31 - PBDT10.4213.99 -26 PBT9.9613.79 -28 NP7.4710.41 -28 Powered by Capital Market - Live News

The Board of Jagsonpal Pharmaceuticals at its meeting held on 03 November 2023 has approved in principle divestment of Company`s Faridabad facility. The said facility has not been operational, and proposed sale will not have any effect on the Company operations.Powered by Capital Market - Live News